Profiling Analysis Reveals Potential Prognostic Biomarkers for Esophageal Cancer Patients Treated with Radiation Therapy
Yu Fan,Tao Li,Qifeng Wang,Jiahua Lv,Qi Li,Yi Wang,Junchao Wang
DOI: https://doi.org/10.1016/j.ijrobp.2017.06.476
IF: 45.3
2017-01-01
Journal of Clinical Oncology
Abstract:e23190 Background: Survival time among esophageal cancer patients undergoing radiotherapy varies considerably. Treatment failure resulting from local recurrence and metastasis reflects varying biological features such as radiosensitivity, invasion, and metastasis. This study aims to explore the genetic characterizations that are associated with prognosis of esophageal cancer patients who have undergone radiotherapy. Methods: We retrospectively reviewed specimens of 21 patients who were treated with radiotherapy. Based on the progression-free-survival (PFS), these patients were divided in to two groups: short PFS group with an average PFS of 6.9 months and long PFS group with an average PFS of 31.9 months. We extracted DNA from paraffin specimens for next generation sequencing. Mutation burden (the sum of mutation frequencies of targeted genes) and copy number aberrance were analyzed by targeted sequencing that covers 1086 genes. Results: We excluded six samples in the mutation burden analysis because of the shortage of coverage of the targeted genes. The mutation burden of 15 genes panel, which included ARID1A, BCL2, BRAF, CDH1, ERBB2, FAT1, LRP1B, MET, MTOR, NOTCH1,NOTCH2, PDGFRA, PTCH1, RB1, STK11, showed a statistically significant difference between the long PFS group and the short PFS group (p value = 0.001408). We then used copy number variation (CNV) kit to detect genes copy number variation between these two groups. The CNV of 9 genes panel, which include ASH1L, CD55, CDK4, CREBBP, FGFR1, MYC, TP53 , TYMS, XRCC3, showed a statistically significant difference between the long PFS group and the short PFS group (p value = 0.03147). Conclusions: Our results suggested that the gene mutation burden and CNV detected by targeted sequencing have a relationship with the prognosis of esophageal cancer patients who had undergone radiotherapy. In this exploratory study, we involved patients with extreme PFS ( < 1 year and > 2 years), which can be expanded in the future. To construct a predictive genetic model of prognosis in esophageal cancer patients, one may also consider analyzing circulating tumor DNA (ctDNA) in serum.